Details of the Drug

General Information of Drug (ID: DM2O8VW)

Drug Name

Eclitasertib

Synonyms

Eclitasertib; 2125450-76-0; DNL758; Eclitasertib [INN]; Eclitasertib [USAN]; SAR443122; DNL-758; 975AT1P9J6; Eclitasertib [USAN:INN]; UNII-975AT1P9J6; WHO 11844; SAR-443122; 3-(Phenylmethyl)-N-((3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido(3,2-b)(1,4)oxazepin-3-yl)-1H-1,2,4-triazole-5-carboxamide; 1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-((3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido(3,2-b)(1,4)oxazepin-3-yl)-; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; ECLITASERTIB [WHO-DD]; CHEMBL4861471; SCHEMBL19207477; GTPL11308; US9815850, Compound 42; BDBM356271; EX-A5731; US9815850, Compound 169; AKOS040759938; AT37390; DNL-758; SAR-443122; example 42 [WO2017136727A2]; MS-26168; HY-114371; CS-0084281

Indication

Disease Entry	ICD 11	Status	REF
Ulcerative colitis	DD71	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C19H18N6O3
Canonical SMILES: CN1C(=O)C(COC2=C1N=CC=C2)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
InChI: InChI=1S/C19H18N6O3/c1-25-17-14(8-5-9-20-17)28-11-13(19(25)27)21-18(26)16-22-15(23-24-16)10-12-6-3-2-4-7-12/h2-9,13H,10-11H2,1H3,(H,21,26)(H,22,23,24)/t13-/m0/s1
InChIKey: XUZICJHIIJCKQQ-ZDUSSCGKSA-N

Cross-matching ID

PubChem CID: 130298939
TTD ID: DWM2Y5

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Receptor-interacting protein 1 (RIPK1)	TTAIQSN	RIPK1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05588843) A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis. U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight